Friday 6 November 2026 Export PTPI’s income statement to Excel — free account

Petros Pharmaceuticals, Inc.

PTPI Healthcare Drug Manufacturers Specialty & Generic

Petros Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $5.1 million, down 12.2% from fiscal 2023.

Revenue: +299.1%
EPS: +75.0%
Free cash flow: +71.3%

Quarter to June 2026, against a year earlier

0.00 0.00 NaN

Follow PTPI

Alert me

Market cap: $1.0M
P/E: 0.0×
Fwd P/E: −0.3×
Dividend yield: —
F-score: 4/9
Altman Z: −16.96
Beneish M: −3.26
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 46.19%

Capital & Financial Ratios $m

Size

Market Cap 1.04

Revenue ttm 5.11

Net income ttm (3.20)

Free cash flow ttm (3.72)

Net debt Q (3.49)

Valuation

P/E 0.00

Forward P/E (0.30)

Price / sales 0.00

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.00

Financial health

Current ratio Q 1.25

Debt / equity Q 0.00

Interest coverage Q (1.44)

Growth

Revenue growth Q +299.12%

Operating income growth Q +45.11%

EPS, this year +67.43%

EPS, next year A +48.83%

Revenue, next year A +7.10%

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

EV/Sales against its own 10 years 32.76%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	13	2	5	3
Receivables	2	0	—	—
Inventory	2	1	—	—
Other	—	6	—	—
	20	7	5	4

	2023	2024	2025	Q'26
Payables	2	1	0	0
ST’ Debt	—	—	—	—
Other	0	15	0	—
	11	18	2	3

Compound Annual Growth %

	10y	5y	3y
Sales	—	(19.98%)	(13.18%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(13.17%)	(30.31%)	(44.40%)

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.02)	(0.30)	—	—	—
’25	(9.37)	(1.20)	(0.03)	1.83	(1.56)
’24	(42.19)	(9.25)	(13.34)	(26.63)	(83.50)
’23	(16.50)	(30.00)	(71.27)	(40.37)	(158.75)
’22	(2.50)	(22.50)	(167.50)	(50.80)	(242.00)
’21	77.50	(55.00)	(42.50)	(187.50)	(207.50)
’20	(307.23)	(419.53)	(240.20)	3.39	(963.58)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	1	1	2	1	5
’23	3	2	2	0	6
’22	2	4	(1)	1	6
’21	4	2	2	(1)	8
’20	2	1	3	3	10
’19	5	4	—	—	16

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(2)	(3)	(1)	(1)	(7)
’24	(1)	(2)	(1)	1	(3)
’23	(1)	(1)	(4)	(2)	(8)
’22	(5)	(4)	(2)	(2)	(13)
’21	0	(2)	(1)	(8)	(12)
’20	(2)	(6)	(3)	(5)	(15)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(2)	(3)	(1)	(1)	(7)
’24	(1)	(2)	(1)	1	(3)
’23	(1)	(1)	(4)	(2)	(8)
’22	(5)	(4)	(2)	(2)	(13)
’21	0	(2)	(1)	(8)	(12)
’20	(2)	(6)	(3)	(5)	(15)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	14	16	10	8	6	6	5	—	5		(15.5%)	5	—	—	—
	Gross margin, %	—	—	25.41	52.32	57.67	79.52	61.79	71.98	76.28	—	118.32		+50.9 pt	Powerpack Petros Pharmaceuticals, Inc.’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(13)	(13)	(11)	(33)	(22)	(9)	(20)	(8)	(1)	(4)	(3)		(11.1%)
	EBT margin, %	0.00	0.00	(78.44)	(212.86)	(230.27)	(115.05)	(334.40)	(140.20)	(13.79)	0.00	0.00		0.0 pt
	Net income	(13)	(13)	(11)	(33)	(21)	(9)	(20)	(8)	(14)	2	(3)		n/m
Per share, $
Per share, $	Revenue	0.00	0.00	2,195.50	1,589.51	446.71	179.16	72.37	66.92	15.93	0.00	0.00		n/m
	Earnings	(7,112.50)	(2,025.42)	(1,712.50)	(3,303.99)	(877.85)	(207.50)	(242.05)	(158.75)	(83.50)	(1.56)	1.47		(60.8%)
	Cash flow	(4,098.06)	(1,772.27)	(1,202.62)	258.42	(715.20)	(272.06)	(154.56)	(87.66)	(8.11)	(0.24)	(0.08)		(66.1%)
	Capex	(1.61)	(0.58)	(0.50)	(7.30)	(0.21)	0.00	0.00	0.00	(0.08)	0.00	0.00		n/m
	Free cash flow	(4,099.67)	(1,772.85)	(1,203.12)	251.12	(715.42)	(272.06)	(154.56)	(87.66)	(8.19)	(0.24)	(0.08)		(66.1%)
	Book value	13,113.72	2,400.97	4,143.95	818.29	816.31	815.25	201.72	138.75	(23.26)	0.10	0.01		(72.9%)
	Shares, m	0	0	0	0	0	0	0	0	0	28	41		+192.3%
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	0.00		0.0
	P/S	—	—	0.00	0.00	2.46	4.65	1.10	0.58	0.78	—	0.00		1.4
	P/B	—	—	0.02	0.00	1.35	1.02	0.40	0.28	0.00	—	0.00		0.4
	EV/Sales	—	—	0.00	0.00	1.48	1.87	1.22	(0.23)	1.75	—	0.62		0.9
	EV/FCF	—	—	3.67	4.81	(0.92)	(1.23)	(0.57)	0.18	(3.40)	—	(0.85)		0.4
Cash, $m
Cash, $m	Operating cash flow	(7)	(11)	(8)	3	(15)	(12)	(13)	(8)	(3)	(7)	(4)		(1.0%)
	Capex	0	0	0	0	0	—	—	—	0	—	0		+30.6%
	Free cash flow	(7)	(11)	(8)	2	(15)	(12)	(13)	(8)	(3)	(7)	(4)		(1.0%)
Balance, $m
Balance, $m	Working capital	24	15	27	(29)	(16)	0	8	10	(11)	3	1		(20.9%)
	Net debt	(26)	(16)	18	12	(9)	(23)	(1)	(6)	(2)	(5)	(3)		(16.4%)
	Shareholders’ equity	24	15	27	8	17	36	17	12	(7)	3	1		(20.9%)
Returns, %
Returns, %	ROA	(66.71)	(59.49)	(48.00)	(74.02)	(32.11)	(13.10)	(40.15)	(41.72)	(120.62)	(553.07)	(334.15)		(486.4) pt
	ROIC	0.00	0.00	(15.53)	(61.53)	(134.43)	(93.20)	(79.46)	(152.21)	0.00	0.00	0.00		0.0 pt
	ROE	(109.61)	(65.55)	(53.24)	(447.74)	(752.67)	(33.90)	(76.70)	(96.02)	(1,164.24)	1,900.89	(710.28)		+2,010.5 pt
People
People	Employees	5	5	8	7	27	24	24	21	18	3	—		(5.5%)
	Revenue/emp, $m	0.00	0.00	1.76	2.23	0.35	0.33	0.25	0.28	0.28	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2024 · latest quarter Dec 2024 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
APUS Apimeds Pharmaceuticals US, Inc.	$4.1M	— (loss-making)	—	—	n/m	−67.94% (below 0%: shrinking)	—	0.00%	Compare
RDHL Redhill Biopharma Ltd.	$3.8M	— (loss-making)	— (loss-making)	−90.32% (below 0%: shrinking)	n/m	−107.31% (below 0%: shrinking)	(7.52%)	0.00%	Compare
BTAIQ BioXcel Therapeutics, Inc.	$2.3M	— (loss-making)	— (loss-making)	+51.67% (above 0%: growing)	n/m	+51.51% (above 0%: growing)	87.91%	(5,600.55%)	Compare
PRFX PainReform Ltd.	$2.3M	— (loss-making)	— (loss-making)	—	n/m	+52.56% (above 0%: growing)	0.00%	0.00%	Compare
AKAN Akanda Corp.	$2.2M	—	—	—	—	−472.01% (below 0%: shrinking)	(197.87%)	0.00%	Compare
SBFM Sunshine Biopharma, Inc.	$2.1M	— (loss-making)	— (loss-making)	−1.56% (below 0%: shrinking)	n/m	+49.38% (above 0%: growing)	26.20%	(17.41%)	Compare
SXTC China SXT Pharmaceuticals, Inc.	$2.0M	— (loss-making)	— (loss-making)	−16.76% (below 0%: shrinking)	+92.67% (above 0%: growing)	−107.59% (below 0%: shrinking)	44.09%	0.00%	Compare
PTPI Petros Pharmaceuticals, Inc.	$1.0M	— (loss-making)	— (loss-making)	+299.12% (above 0%: growing)	n/m	+71.27% (above 0%: growing)	359.80%	0.00%
IMCC IM Cannabis Corp.	$980.0K	— (loss-making)	— (loss-making)	−40.28% (below 0%: shrinking)	n/m	−266.81% (below 0%: shrinking)	19.83%	(27.54%)	Compare
Median of peers	$2.3M	—	—	−16.76%	—	−87.62%	19.83%	0.00%

All 84 Drug Manufacturers Specialty & Generic stocks →

Petros Pharmaceuticals, Inc. (PTPI) Latest News

7 Nov

Impact 3 · 4:05 PM · GlobeNewswire

Delisting of Securities from The Nasdaq Stock Market

25 Jun

Impact 4 · 9:15 AM · ACCESS Newswire

Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position

21 May

Impact 4 · 9:00 AM · ACCESS Newswire

Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets

Impact 4 · 9:15 AM · ACCESSWIRE

Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA

20 May

Impact 4 · 9:15 AM · ACCESS Newswire

Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer

6 May

Impact 4 · 9:20 AM · ACCESS Newswire

Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform

1 May

Impact 4 · 9:20 AM · ACCESS Newswire

Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches

29 Apr

Impact 4 · 9:20 AM

Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms

2 Apr

Impact 4 · 9:15 AM · ACCESSWIRE

Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status

Impact 3 · 7:49 AM

Petros Pharmaceuticals Full Year 2024 Earnings: US$3.34 loss per share (vs US$6.35 loss in FY 2023)

20 Mar

Impact 4 · 9:15 AM · ACCESS Newswire

Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications

25 Feb

Impact 4 · 9:20 AM · ACCESS Newswire

Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study

18 Feb

Impact 3 · 9:25 AM

Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants

7 Jan

Impact 4 · 9:15 AM

Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules

19 Dec

Impact 4 · 9:15 AM · ACCESSWIRE

Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment”

17 Dec

Impact 4 · 9:00 AM

Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually

16 Nov

Impact 3 · 8:08 AM earnings

Petros Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

11 Sep

Impact 4 · 9:15 AM · ACCESSWIRE

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

3 Sep

Impact 3 · 9:00 AM · ACCESSWIRE

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

17 Aug

Impact 3 · 9:56 AM · Simply Wall St.

Petros Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations

29 Jul

Impact 4 · 9:20 AM · ACCESSWIRE

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

16 Jul

Impact 4 · 9:00 AM · ACCESSWIRE

Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance

17 Jun

Impact 4 · 3:08 AM · Benzinga

EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says

29 May

Impact 4 · 9:00 AM · ACCESSWIRE

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch

14 May

Impact 4 · 9:15 AM · ACCESSWIRE

Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe

Impact 4 · 7:00 AM · GlobeNewswire

Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals

23 Apr

Impact 4 · 9:15 AM · ACCESSWIRE

Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health

16 Apr

Impact 4 · 9:15 AM · ACCESSWIRE

Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)

19 Mar

Impact 4 · 9:00 AM · ACCESSWIRE

Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider

14 Feb

Impact 4 · 9:15 AM · ACCESSWIRE

Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Petros Pharmaceuticals, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Petros Pharmaceuticals, Inc. (PTPI) Latest News

7 Nov

25 Jun

21 May

20 May

6 May

1 May

29 Apr

2 Apr

20 Mar

25 Feb

18 Feb

7 Jan

19 Dec

17 Dec

16 Nov

11 Sep

3 Sep

17 Aug

29 Jul

16 Jul

17 Jun

29 May

14 May

23 Apr

16 Apr

19 Mar

14 Feb

Stockrow Weekly